Caribou Biosciences (CRBU) Tax Provisions (2020 - 2021)
Caribou Biosciences (CRBU) posted quarterly Tax Provisions of $321000.0 for Q4 2021, up 190.68% year-over-year from $110431.5 in Q4 2020, and up 190.68% quarter-over-quarter from -$354000.0 in Q4 2020.
Caribou Biosciences (CRBU) Tax Provisions (2020 - 2021) Analysis & Trends
Caribou Biosciences (CRBU) has reported Tax Provisions for 2 consecutive years, with $321000.0 the latest figure, recorded in Q4 2021.
- In Q4 2021, Tax Provisions rose 190.68% year-over-year to $321000.0; the TTM figure through Dec 2021 stood at $321000.0 (up 117.65% YoY), while the FY2025 annual figure was -$550000.0, down 6011.11% from the prior year.
- Tax Provisions advanced to $321000.0 in Q4 2021 per CRBU's latest filing, from -$354000.0 in the prior quarter.
- Across five years, Tax Provisions topped out at $321000.0 in Q4 2021 and bottomed at -$1.2 million in Q1 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 292.00 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 230.90 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 59.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 15.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 75.45 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 13.31 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -90.33 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.90 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Caribou Biosciences | 166.63 Mn | 54.31 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 321,000.00 |
| Dec 31, 2020 | -354,000.00 |
| Sep 30, 2020 | -213,000.00 |
| Jun 30, 2020 | -50,000.00 |
| Mar 31, 2020 | -1.20 Mn |